AHA 2014:机械与人工心肺复苏效果相当(PARAMEDIC)

2014-11-19 CMT 中国医学论坛报今日循环

美国心脏学会(AHA)2014年科学年会上公布且11月16日在线发表于Lancet的一项随机试验PARAMEDIC结果显示,在改善心脏骤停患者30天生存率方面,机械(LUCAS-2)心肺复苏相较于人工心肺复苏没有明显优势。研究内容与结果研究者将院外心脏骤停的患者随机分至LUCAS-2胸部按压组(实验组)和人工心肺复苏组(对照组),通过意向治疗分析比较两组间心脏骤停30天内的生存率。结果为,实验组纳

美国心脏学会(AHA)2014年科学年会上公布且11月16日在线发表于Lancet的一项随机试验PARAMEDIC结果显示,在改善心脏骤停患者30天生存率方面,机械(LUCAS-2)心肺复苏相较于人工心肺复苏没有明显优势。

研究内容与结果

研究者将院外心脏骤停的患者随机分至LUCAS-2胸部按压组(实验组)和人工心肺复苏组(对照组),通过意向治疗分析比较两组间心脏骤停30天内的生存率。

结果为,实验组纳入1652例患者,对照组纳入2819 例患者,通过意向处理分析,实验组和对照组30天内的生存率分别为6%和7%(校正OR=0.86 ,95% CI为0.64~1.15),两组间没有显著差异,并且都没有严重的不良事件报告。

研究者英国沃里克大学Gavin Perkins教授观点

在该研究中,机械心肺复苏虽然在改善生存率方面未表现出优势,但是却有其实际应用价值,例如,能够保障在患者转运过程中在移动车辆上进行心肺复苏的安全性和质量,能够解放医生的双手完成更多工作。急救部门的领导可能选择引进或继续使用机械心肺复苏,但需要保证人员接受足够的训练以确保心肺复苏的质量。

其他专家评论

新加坡中央医院Marcus Eng Hock Ong和Venkataraman Anantharaman 院外人工心肺复苏很难达到最佳效果,会影响患者生存。而机械复苏在施行时可以连续不间断且质量始终如一,使其成为很有吸引力的选择。

虽然试验结果并没有显示机械心肺复苏有明显的生存获益优势,但该研究描绘了大型复苏试验的复杂性和难度,并说明了在评估任何新技术中注意实施和训练的重要性。试验组临床结果没有明显优势,也可能不是由于设备或治疗本身的原因,而是培训、对方案的依从性和实施的原因。

试验虽然未能就人工和机械心肺复苏之争给出定论,但是开始关注实施和质量的重要性。要获得高质量人工心肺复苏需要进行训练和质量评估,机械心肺复苏同样需要进行训练和并注实践,且机械心肺复苏花费更高。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858591, encodeId=47981858591b6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jan 22 05:21:00 CST 2015, time=2015-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684387, encodeId=3fe3168438e9f, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Mon Mar 02 12:21:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267228, encodeId=246e126e22893, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305349, encodeId=378b130534978, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606327, encodeId=6331160632e8b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=)]
    2015-01-22 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858591, encodeId=47981858591b6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jan 22 05:21:00 CST 2015, time=2015-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684387, encodeId=3fe3168438e9f, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Mon Mar 02 12:21:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267228, encodeId=246e126e22893, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305349, encodeId=378b130534978, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606327, encodeId=6331160632e8b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=)]
    2015-03-02 aids222
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858591, encodeId=47981858591b6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jan 22 05:21:00 CST 2015, time=2015-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684387, encodeId=3fe3168438e9f, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Mon Mar 02 12:21:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267228, encodeId=246e126e22893, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305349, encodeId=378b130534978, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606327, encodeId=6331160632e8b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=)]
    2014-11-21 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1858591, encodeId=47981858591b6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jan 22 05:21:00 CST 2015, time=2015-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684387, encodeId=3fe3168438e9f, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Mon Mar 02 12:21:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267228, encodeId=246e126e22893, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305349, encodeId=378b130534978, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606327, encodeId=6331160632e8b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=)]
    2014-11-21 lizhou0204
  5. [GetPortalCommentsPageByObjectIdResponse(id=1858591, encodeId=47981858591b6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jan 22 05:21:00 CST 2015, time=2015-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684387, encodeId=3fe3168438e9f, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Mon Mar 02 12:21:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267228, encodeId=246e126e22893, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305349, encodeId=378b130534978, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606327, encodeId=6331160632e8b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 21 00:21:00 CST 2014, time=2014-11-21, status=1, ipAttribution=)]

相关资讯

NEJM:心肺复苏时家属在场会产生积极影响

心肺复苏(CPR)期间患者家庭成员在场对他们本身和医疗小组有什么影响仍存在争议。法国巴黎公共救助医院(AP-HP)紧急医疗救助服务部(SAMU)的研究者对此进行了深入研究,他们发现,CPR实施过程中患者家属在场会对心理学变量的结果产生积极的影响,并且未干扰医疗投入程度、未加重医疗保健组的应激、也未导致医疗法律索赔。相关论文发表于国际权威杂志NEJM 2013年6月份在线版。 研究纳入了因心脏停搏

Anesth Analg:富氢液可提高心肺复苏后生存率

在全世界范围内,心跳骤停是引发死亡的一个主要原因。随着技术手段的不断更新,心肺复苏的成功率已经提到30%-40%。但是令人遗憾的是,这些被成功复苏的病人中约有3/4的人最终还是死亡或者遗留永久性的神经系统功能损害。 低温治疗技术在临床上已经得到了验证,可以有效的提高患者的预后。我们现在急需寻找一种药物配合低温治疗来改善心肺复苏之后的病人的预后。 富氢液是一种富含氢气的生理盐水,其特点是

基于更新指南的心肺复苏改善心搏骤停患者预后

     美国学者的一项研究表明,如果接受基于更新指南的心肺复苏(CPR),不可电击心搏骤停患者就更有可能生存。论文4月2日在线发表于《循环》(Circulation)杂志。   美国心脏学会于2005年更新了其CPR指南,推荐更少中断的更大程度胸外按压。2010年更新指南继续强调了胸外按压。2005年指南公布后,数项研究显示可电击心搏骤停生存率出现改善。然而,新证据表明大部分心搏骤停为对电击

心肺复苏研究的若干新进展

自2010年美国心脏学会心肺复苏(CPR)与心J&L管病急救(ECC)指南(简称国际CPR指南)修订已经三年时间,每次指南的实践和推广,都会引起新的研究热点和理论争议。随着循证医学与转化医学的不断发展与广泛应用,CPR的研究近年来也取得了一定的进展。 1.通气在心肺复苏中的作用 2010年国际CPR指南将成人和儿童(不包括新生儿)基本生命支持修订为“

NEJM:喉罩气道管理用于急诊心肺复苏安全有效

2013年11月14日,NEJM临床视频版块发表了喉罩( LMA )气道管理在心跳呼吸骤停时的使用,引起各方强烈关注。NEJM近期就上述视频发表了读者来信及作者回复,现编译如下。伯明翰阿拉巴马大学医学院的Henry博士等认为,视频反映了喉罩( LMA )气道管理应用于心跳呼吸骤停的实用性。但现有支持急诊应用该装置和其他声门上通气装置(如喉管)的数据有限,且与视频不一致。Lighthall等声明LM

JAMA:普及远程指导心肺复苏术意义重大

早在1960年,就有人提出闭式胸外按压术可以用来治疗心脏骤停,也为治疗这种头号致死性疾病提出了一个具有变革意义的理论基础。作者甚至激动的写道“任何人在任何地点都可以进行心脏复苏术操作,而手术器材就是我们的双手”。【原文下载】今天,这种急救措施已经演变成为我们所熟知的心肺复苏术(CPR)。通过CPR,心脏骤停的存活率提高了2至3倍。起初,人们认为只有临床医生才可以实施CPR,但是类似CPR的复苏术成